Search Results
Your search for AT matches 28914 pages
Showing 5951 - 6000Study Finds Lumpectomy May Be as Effective as Mastectomy for Patients With Nonmetastatic Breast Cancer Younger Than 40
Young women with nonmetastatic breast cancer have similar survival rates whether they are treated with mastectomy or lumpectomy, despite tumors that are typically more aggressive and discovered at a later stage compared to their older counterparts. These findings were from a recent study examining...
Positive Lymph Nodes May Not Be an Indicator for Chemotherapy in Older Patients With Breast Cancer
Positive lymph node status may not be a reliable indicator of the need for adjuvant chemotherapy, and sentinel node biopsy may be unnecessary in older women with certain low-risk cancers, according to a new study presented by Nicholson et al at the American Society of Breast Surgeons 23rd Annual...
Study Finds COVID-19 Restrictions Delayed Breast Cancer Care at a Safety-Net Hospital
The 1-year local COVID-19 restrictions negatively impacted breast cancer stage at presentation, time to treatment, and time to surgery at an urban safety-net hospital, increasing the vulnerability of an already high-risk population. These findings were from a recent study presented by Kapp et al at ...
Prognostic Value of sTILs in Young Women With Node-Negative Triple-Negative Breast Cancer Who Did Not Receive (Neo)Adjuvant Systemic Therapy
In a Dutch retrospective study reported in the Journal of Clinical Oncology, de Jong et al found that higher levels of stromal tumor-infiltrating lymphocytes (sTILs) were associated with “excellent prognosis” in young women with node-negative triple-negative breast cancer who did not receive...
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma
In the phase III TAPPAS trial reported in JAMA Oncology, Jones et al found that the addition of carotuximab to pazopanib did not improve progression-free survival in patients with advanced angiosarcoma. Carotuximab is an IgG1 antibody that binds endoglin, which is highly expressed on proliferating...
Protecting the Immunocompromised From COVID-19: Practical Information for Physicians
COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah, MD, a hematologic oncologist at Memorial...
FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice) for adult and pediatric patients aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. PROS encompasses a group of rare...
Anetumab Ravtansine vs Vinorelbine in Relapsed Mesothelin-Positive Advanced Malignant Pleural Mesothelioma
In the phase II ARCS-M trial reported in The Lancet Oncology, Hedy L. Kindler, MD, FASCO, and colleagues found that the antimesothelin antibody–tubulin inhibitor conjugate anetumab ravtansine did not improve progression-free survival vs vinorelbine as second-line treatment for patients with...
Combined BCMA and CD19 CAR T Cells in Relapsed or Refractory Multiple Myeloma: Long-Term Follow-up
In a long-term follow-up of a Chinese phase II study reported in the Journal of Clinical Oncology, Wang et al found that the combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells produced durable responses and favorable survival outcomes in...
Expert Point of View: Sandy Srinivas, MD
“Prior to these two studies, smaller studies showed a lack of response to PARP [poly (ADP-ribose) polymerase] inhibitors in previously treated patients with urothelial cancer, both as monotherapy and in combinations,” said formal discussant of the BAYOU and ATLANTIS trials, Sandy Srinivas, MD,...
Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?
Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...
Expert Point of View: Alexander T. Pearson, MD, PhD
Alexander T. Pearson, MD, PhD, Assistant Professor of Medicine at the University of Chicago, commended the artificial intelligence (AI)-augmented, ultrasound-based platform for screening and staging of thyroid cancer. “In this study, Dr. Chan and colleagues processed high-resolution ultrasound...
Study Finds AI Ultrasound Platform Can Predict Thyroid Malignancy, Pathologic Stage, and BRAF Mutation Status
An artificial intelligence (AI) ultrasound platform that incorporates multiple methods of machine learning can accurately predict thyroid malignancy as well as pathologic and genomic outcomes, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Findings from...
Tumor Budding May Provide Independent Prognostic Value for Disease-Free and Overall Survival in Patients With Stage III Colon Cancer
Tumor budding is an emerging prognostic biomarker in colon cancer and currently influences decision-making in patients with pT1 and stage II colon cancer. In stage III colon cancer, its prognostic impact has been limited to small and retrospective cohorts. In a post hoc analysis of the IDEA-France...
Study Explores Racial Disparities Among Patients Undergoing Gastrointestinal Cancer Surgery
Black adult patients are more likely than White patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center published by Bakkila et al in JAMA Network Open. “The COVID-19 pandemic has brought to light previously reported race...
Immune-Related Adverse Events With Immune Checkpoint Inhibitor Treatment for Melanoma in Older White Patients
In a population-based cohort study reported in JAMA Network Open, Schonfeld et al identified the incidence of immune-related adverse events among White patients aged ≥ 65 years with newly diagnosed melanoma treated with immune checkpoint inhibitors. They compared the risk of these adverse events...
Addition of Sorafenib to Standard Chemotherapy in Pediatric Patients With High Allelic Ratio FLT3-ITD–Positive AML
In an analysis from the Children’s Oncology Group protocol AAML1013 reported in the Journal of Clinical Oncology, Pollard et al found that the addition of sorafenib to standard chemotherapy may benefit pediatric patients with high allelic ratio FLT3-ITD–positive acute myeloid leukemia (AML). Study...
Advances in Managing Cardiac Side Effects Associated With Breast Cancer Treatment
Guideline-directed medical therapy for the prevention and treatment of cardiotoxicity is improving quality of life and oncologic outcomes associated with breast cancer treatment, according to Jean-Bernard Durand, MD, FACP, FCCP, FACC, FHFSA, Professor of Medicine at The University of Texas MD...
Telemedicine vs In-Person Postoperative Follow-up After Inpatient Oncologic Surgery
In a single-institution retrospective study reported in JCO Oncology Practice, Uppal et al found that telemedicine postoperative visits during the COVID-19 pandemic did not result in increased unplanned hospital readmissions vs in-person postoperative visits among patients undergoing elective...
Hyperthermic Intraperitoneal Chemotherapy With Primary or Interval Cytoreductive Surgery for Advanced Ovarian Cancer
In a Korean study reported in JAMA Surgery, Lim et al found that hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery did not improve progression-free survival vs no HIPEC in women with newly diagnosed stage III or IV epithelial ovarian cancer. A benefit of HIPEC was...
Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in JAMA Oncology, Li et al found that induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) prior to concurrent chemoradiation was associated with improved failure-free survival vs induction therapy with cisplatin and fluorouracil (PF) in...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to allow...
Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
Effect of Traditional Eligibility Criteria on Enrollment of Black Patients in Pancreatic Cancer Clinical Trials
In a single-center study reported in the Journal of Clinical Oncology, Riner et al found that traditional eligibility criteria for clinical trials in pancreatic ductal adenocarcinoma excluded a higher proportion of Black vs White patients and identified factors that commonly led to exclusion. As...
DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...
Collaboration Finds International Disparities in Screening, Treatment, and Outcomes for Patients With Lung Cancer
A consensus reached by a lung cancer clinical community within the International Cancer Benchmarking Partnership (ICBP) presented by Lynch et al at the European Lung Cancer Congress (Abstract 196P) has highlighted international disparities in the management and outcomes of patients with lung cancer ...
Association of Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy With Risk of Subsequent Peritoneal Carcinomatosis
Findings from a meta-analysis of individual patient data were reported in the Journal of Clinical Oncology. Steenbeek et al found that among women with BRCA1/2 pathogenic variants who underwent risk-reducing salpingo-oophorectomy for prevention of epithelial ovarian cancer, those with serous tubal...
Study Compares Surveillance Methods and Schedules in Stage I Testicular Seminoma
In the phase III TRISST trial reported in the Journal of Clinical Oncology, Joffe et al found that surveillance with magnetic resonance imaging (MRI) was noninferior to computed tomography (CT) in detecting advanced relapse in patients with stage I testicular seminoma who had undergone orchiectomy...
Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC
More than half of patients diagnosed with advanced non–small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the past 5 years, according to real-world data from a Spanish national registry study reported by Calvo de Juan et al at the European Lung Cancer...
ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
As reported in The Lancet Oncology by Rebecca Kristeleit, MD, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations. Study...
Cabozantinib Plus Nivolumab in Advanced Non–Clear Cell Renal Cell Carcinoma
In a single-institution phase II study reported in the Journal of Clinical Oncology, Chung-Han Lee, MD, PhD, and colleagues found that the combination of cabozantinib and nivolumab was active in patients with advanced non–clear cell renal cell carcinoma (RCC) variants, particularly those with...
Long-Term Survival Outcomes With Adjuvant Capecitabine in Biliary Tract Cancer
As reported in the Journal of Clinical Oncology by Bridgewater et al, long-term follow-up of the phase III BILCAP study has shown a continued survival benefit with adjuvant capecitabine therapy in patients with curatively resected biliary tract cancer. In the multicenter trial, 447 patients with...
Emerging Endocrine Therapies for the Management of Breast Cancer
Novel hormonal therapies for breast cancer could provide additional therapeutic options for patients with hormone receptor–positive breast cancer. The emerging landscape for these new agents was described at the 2022 Miami Breast Cancer Conference, sponsored by PER, by Aditya Bardia, MD, MPH,...
Study Finds Black Patients With Cancer Diagnosed With COVID-19 Have Worse Outcomes Than White Patients
Black patients with cancer experienced significantly worse outcomes after a COVID-19 diagnosis than non-Hispanic White patients, according to findings published by Fu et al in JAMA Network Open. Investigators from the COVID-19 and Cancer Consortium (CCC19) studied the electronic health records of...
Thickness-Specific Incidence of Cutaneous Melanoma in the United States
In a population-based cohort study reported in JAMA Oncology, Chen et al found that the incidence of overall cutaneous melanoma and thinner tumors was stable in the United States from 2010 to 2018, with an increased incidence of the thickest (T4) melanomas being observed. Lower socioeconomic status ...
Third COVID-19 Vaccine Dose May Improve Immune Response in Patients With Lymphoma
New research has found that the weakened immune systems of patients with lymphoma may improve after they receive a third COVID-19 vaccination. Patients with lymphoma have defects in their immune system that restrict its response to vaccination; despite this, a study published by Lim et al in Nature ...
Risk of Colorectal Cancer May Be Linked to Cumulative Time With Excess Body Weight
In a German study reported in JAMA Oncology, Li et al found that assessment of risk of colorectal cancer based on cumulative lifetime excess weight may be more accurate than risk indicated by single body mass index (BMI) measurements. As stated by the investigators, “Excess weight is associated...
PD-1 Inhibition in Patients With Classic or Endemic Kaposi Sarcoma
In a French phase II study reported in The Lancet Oncology, Delyon et al found that pembrolizumab produced a high response rate in patients with classic or endemic Kaposi sarcoma with progressive cutaneous extension requiring systemic treatment. As stated by the investigators, “Although the...
Short-Term Radiotherapy Plus Preoperative Chemotherapy vs Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer
In the Chinese phase III STELLAR trial reported in the Journal of Clinical Oncology, Jin et al found that preoperative short-term radiotherapy followed by chemotherapy was not inferior in 3-year disease-free survival vs a standard schedule of long-term chemoradiotherapy in patients with locally...
Results From MAPPYACTS Trial Show the Feasibility and Benefit of Molecular Profiling at Cancer Recurrence in Pediatric Patients
Despite advances in treatment for pediatric patients, cancer remains the primary cause of disease-related mortality in children and adolescents. Data from the international clinical trial MAPPYACTS, which aims to define tumor molecular profiles in pediatric patients with recurrent/refractory...
Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers
In a study reported in the Journal of Clinical Oncology, David R. Freyer, DO, MS, and colleagues found that clinicians consistently undergraded—and caregivers frequently overgraded—the severity of adverse events experienced by children with cancer. Study Details The study included 438...
Study Evaluates Response-Based Immunotherapy Strategy in Patients With Advanced Urothelial Carcinoma
In a phase II study (TITAN-TCC) reported in the Journal of Clinical Oncology, Grimm et al found that a nivolumab/ipilimumab boost in patients with advanced urothelial cancer who did not respond to nivolumab monotherapy alone increased objective response rates, with the benefit being greatest in...
Guideline-Concordant Surgery and Adjuvant Chemotherapy for Early-Stage NSCLC
In a retrospective cohort study reported in JAMA Oncology, Kenneth L. Kehl, MD, MPH, and colleagues found that only a slight majority of patients with early-stage non–small cell lung cancer (NSCLC) who were enrolled in a U.S. screening study (ALCHEMIST) received guideline-recommended adequate lymph ...
How ASCO, ECO, and WHO Are Marshalling Resources to Provide Care for Ukrainian Civilians and Refugees With Cancer
Since Russia invaded Ukraine on February 24, the number of attacks on health-care facilities continues to mount. According to the World Health Organization (WHO), as of March 16, there have been 43 attacks on health facilities, including 34 attacks that have directly impacted health facilities and...
Expert Point of View: E. Gabriela Chiorean, MD
The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy of ...
CodeBreaK 100: Sotorasib Shows Activity in KRAS G12C–Mutated Pancreatic Cancer
Promising activity in metastatic pancreatic cancer was shown by sotorasib, an inhibitor of the KRAS G12C mutation, in the phase I/II CodeBreaK 100 study presented by John H. Strickler, MD, Associate Professor of Medicine at Duke University Medical Center, Durham, North Carolina, during the February ...
Expert Point of View: Mandana Kamgar, MD, MPH
The ASCO Post invited Mandana Kamgar, MD, MPH, Assistant Professor of Medicine at the Medical College of Wisconsin, LaBahn Pancreatic Cancer Program, Milwaukee, to comment on the KRYSTAL-1 trial. “The KRYSTAL-1 study in totality is a multiphase and multiarm ongoing study exploring the role of...
KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer
A disease control rate of 100% was achieved in gastrointestinal cancers treated with the KRAS G12C inhibitor adagrasib in the phase II KRYSTAL-1 trial, presented at the 2022 ASCO Gastrointestinal Cancers Symposium.1 The population included primarily those with pancreatic cancer; other noncolorectal ...
Expert Point of View: Anthony El-Khoueiry, MD
Anthony El-Khoueiry, MD, Member of the Section of Gastrointestinal Cancers, Director of the phase I program, and Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and USC Norris Comprehensive Cancer Center, said the findings of the...
HIMALAYA Trial: First-Line Tremelimumab Plus Durvalumab Improves Overall Survival in Unresectable Hepatocellular Carcinoma
Patients with advanced, unresectable hepatocellular carcinoma may be gaining another first-line treatment option. In the global phase III HIMALAYA trial, a single priming dose of tremelimumab plus regular-interval durvalumab significantly improved overall survival, according to Ghassan K....
